Neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) are biomarkers of
neuronal injury measurable in cerebrospinal fluid (CSF) and blood. Despite their potential …

This narrative review explores the current landscape of blood biomarkers in Frontotemporal
dementia (FTD). Neurofilament light chain (NfL) may be useful in the differentiation of …

Objective Research suggests that recurrent seizures may lead to neuronal injury.
Neurofilament light chain protein (NfL) and glial fibrillary acidic protein (GFAP) levels …

Accelerated brain ageing has been observed in multiple psychiatric disorders. This study
examined whether relationships between age and plasma neurofilament light (NfL) protein …

INTRODUCTION People with neurodegenerative disorders (ND) frequently face diagnostic
delay and misdiagnosis. We investigated blood and cerebrospinal fluid (CSF) neurofilament …

Study Design Measurements of plasma NfL and cortical thickness were obtained from 39
individuals with TRS, and 43 healthy controls. T1-weighted magnetic resonance imaging …

Objective Timely, accurate distinction between behavioural variant frontotemporal dementia
(bvFTD) and primary psychiatric disorders (PPD) is a clinical challenge. Blood biomarkers …

Severe mental disorders (SMDs), such as schizophrenia (SZ), bipolar disorder (BD), and
major depressive disorder (MDD), are heterogeneous psychiatric diseases that impose a …

Objective We investigated diagnostic utility of phosphorylated tau 217 and 181 (ptau217,
ptau181), glial fibrillary acidic protein (GFAP), amyloid beta 42 and 40 (Aβ42, Aβ40), and …

Cerebrospinal fluid (CSF) biomarkers are currently the only clinically validated biofluid
diagnostic test for Alzheimer's Disease (AD) available in Australia. Testing of CSF …